Company Filing History:
6 out of 93 
1 out of 1,743 
1 out of 14 Years Active: 1988-2009
Title: Herve Bazin: Innovator in Immunology
Introduction
Herve Bazin is a notable inventor based in Brussels, Belgium, recognized for his contributions to the field of immunology. With a total of six patents to his name, Bazin has made significant strides in understanding and manipulating immune responses in human patients.
Latest Patents
One of Bazin's latest patents is focused on a composition comprising the LO-CD2a antibody. This invention relates to methods of using such antibodies or molecules that bind to the same epitope to prevent and inhibit immune responses, particularly those mediated by T cells or natural killer cells. The administration of an effective amount of the LO-CD2a antibody can prevent or inhibit graft rejection, graft versus host disease, or autoimmune diseases. Another significant patent involves the apoptosis of naive human NK cells through the crosslinking of their FcγRIIIa molecules with a rat IgG2b (LO-CD2a/BTI-322) or its IgG1 humanized monoclonal antibody. This research demonstrates that naive NK cells can undergo rapid apoptosis after stimulation, which is independent of Fas-ligand and mRNA synthesis, and does not require cell contact.
Career Highlights
Bazin has worked with prestigious institutions such as Université Catholique de Louvain and the Institut National de la Santé et de la Recherche Médicale. His work has contributed to advancements in immunotherapy and the understanding of NK cell behavior in response to various stimuli.
Collaborations
Some of Bazin's notable coworkers include Dominique Latinne and Robert Frank, who have collaborated with him on various research projects.
Conclusion
Herve Bazin's innovative work in immunology, particularly regarding the LO-CD2a antibody and NK cell apoptosis, showcases his significant contributions to medical science. His patents reflect a commitment to advancing our understanding of immune responses and improving patient outcomes.